BiconY Therapeutics

BiconY Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of bispecific antibody therapeutics for oncology. The company's core technology, the BiconY platform, is designed to create conditionally active bispecific antibodies that trigger T-cell mediated killing only in the presence of specific tumor antigens, minimizing off-tumor side effects. Their lead candidate, BY001, is a bispecific antibody targeting EpCAM and CD3 currently undergoing clinical evaluation in patients with advanced solid tumors. BiconY aims to address the limitations of current T-cell engagers by improving the safety profile and therapeutic window for treating solid tumors. The company is headquartered in Suzhou, China, and is supported by leading venture capital firms.